Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...

This article discusses the DOJ’s growing crackdown on healthcare fraud, focusing on illegal speaker programs like Gilead’s $202 million settlement. It stresses the importance of strong compliance, ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.

The U.S. Supreme Court preserved the U.S. Preventative Services Task Force coverage mandate that requires payers to cover ...

Shares of Gilead Sciences Inc. rallied 2.83% to $110.67 Friday, on what proved to be an all-around great trading session for ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.